AUTOLUS THERAPEUTICS PLC

(AUTL)
  Report
Delayed Nasdaq  -  04:00 2022-06-24 pm EDT
2.570 USD   +2.80%
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Maintains Buy Rating
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/17/2022 06/21/2022 06/22/2022 06/23/2022 06/24/2022 Date
2.22(c) 2.39(c) 2.36(c) 2.5(c) 2.57(c) Last
185 099 109 128 92 087 225 626 123 456 Volume
+7.77% +7.66% -1.26% +5.93% +2.80% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 0,77 M - -
Net income 2022 -157 M - -
Net cash position 2022 278 M - -
P/E ratio 2022 -1,51x
Yield 2022 -
Sales 2023 12,6 M - -
Net income 2023 -170 M - -
Net cash position 2023 279 M - -
P/E ratio 2023 -1,50x
Yield 2023 -
Capitalization 234 M 234 M -
EV / Sales 2022 -57,0x
EV / Sales 2023 -3,62x
Nbr of Employees 326
Free-Float 9,71%
More Financials
Company
Autolus Therapeutics PLC is a biopharmaceutical company. The Company is focused on developing programmed T cell therapies for the treatment of cancer. It has a pipeline of product candidates in development for the treatment of hematological malignancies and solid tumors. Its lead clinical programs include AUTO1 (obecabtagene autoleucel, Obe-Cel), AUTO1/22, AUTO4, AUTO6NG and AUTO8. Obe-cel is a CD19 CAR T cell... 
Sector
Biotechnology & Medical Research
Calendar
06/28 | 03:00amShareholder meeting
More about the company
Ratings of Autolus Therapeutics plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about AUTOLUS THERAPEUTICS PLC
06/21European ADRs Rise Sharply in Tuesday Trading
MT
06/15European ADRs Move Higher in Wednesday Trading
MT
06/14Truist Securities Adjusts Price Target for Autolus Therapeutics to $11 From $13, Mainta..
MT
06/13European ADRs Fall Sharply Lower in Monday Trading
MT
06/13TRANSCRIPT : Autolus Therapeutics plc - Special Call
CI
06/10Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Associat..
GL
06/10Autolus Therapeutics Presents Clinical Data Updates at the European Hematology Associat..
AQ
06/09European ADRs Move Lower in Thursday Trading
MT
06/01AUTOLUS THERAPEUTICS : Notice of Annual General Meeting - Form 6-K
PU
06/01European ADRs Move Lower in Wednesday Trading
MT
05/31Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
GL
05/31Autolus to hold Annual General Meeting (AGM) of Shareholders on Tuesday, June 28, 2022
GL
05/31European ADRs Nudge Higher in Tuesday Trading
MT
05/27European ADRs Move Higher in Friday Trading
MT
05/27Autolus Therapeutics to Participate in the Jefferies Healthcare Conference, being held ..
GL
More news
News in other languages on AUTOLUS THERAPEUTICS PLC
06/21Les ADR européens en forte hausse dans les échanges de mardi
06/15Les ADR européens sont en hausse mercredi
06/13Les ADR européens chutent fortement dans les échanges de lundi
06/09Les ADR européens sont en baisse jeudi
06/01Les ADR européens sont en baisse mercredi
More news
Analyst Recommendations on AUTOLUS THERAPEUTICS PLC
More recommendations
Chart AUTOLUS THERAPEUTICS PLC
Duration : Period :
Autolus Therapeutics plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AUTOLUS THERAPEUTICS PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 10
Last Close Price 2,57 $
Average target price 11,39 $
Spread / Average Target 343%
EPS Revisions
Managers and Directors
Christian Martin Itin Chief Executive Officer & Director
Lucinda Crabtree Chief Financial Officer
John H. Johnson Non-Executive Chairman
Martin Pulé Chief Scientific Officer & Senior Vice President
David Brochu Vice President-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
AUTOLUS THERAPEUTICS PLC-50.48%234
GILEAD SCIENCES, INC.-13.12%79 122
VERTEX PHARMACEUTICALS33.22%74 821
REGENERON PHARMACEUTICALS, INC.-3.01%65 993
WUXI APPTEC CO., LTD.-13.42%44 742
BIONTECH SE-48.01%32 574